The rapid emergence of viruses has caused widespread pandemics. This is exemplified by COVID-19, which has caught public health communities unprepared with no viable therapeutic treatments.
READDI is retooling the drug discovery and development process to rapidly develop new antiviral drug solutions for future. These pandemics are bigger than any one company, government or academy. A unique public-private partnership accelerated by open science, READDI has a goal of developing multiple “on the shelf” clinical assets so that we are prepared for the next global health pandemic.
READDI aims to raise $125 million to generate 5 new drugs with human safety and dosing data (up to Phase 2 clinical trials) in 5 years to be ready for the next pandemic. This philanthropic investment will enable the world’s top researchers to work together to unlock effective therapeutic options so we are never caught off-guard again.
READDI brings together leaders from industry, government, philanthropic organizations and academic research institutions to leverage existing platforms and accelerate the development of new antiviral drugs.